U.S. Markets close in 4 hrs 9 mins
  • S&P 500

    4,410.10
    +55.91 (+1.28%)
     
  • Dow 30

    34,402.11
    +482.27 (+1.42%)
     
  • Nasdaq

    14,920.48
    +174.09 (+1.18%)
     
  • Russell 2000

    2,224.62
    +38.44 (+1.76%)
     
  • Crude Oil

    70.51
    -0.05 (-0.07%)
     
  • Gold

    1,778.30
    +0.10 (+0.01%)
     
  • Silver

    22.80
    +0.23 (+1.01%)
     
  • EUR/USD

    1.1744
    +0.0014 (+0.1174%)
     
  • 10-Yr Bond

    1.3160
    -0.0080 (-0.60%)
     
  • Vix

    21.21
    -3.15 (-12.93%)
     
  • GBP/USD

    1.3666
    +0.0002 (+0.0164%)
     
  • USD/JPY

    109.5840
    +0.3640 (+0.3333%)
     
  • BTC-USD

    44,590.88
    -3,435.44 (-7.15%)
     
  • CMC Crypto 200

    1,075.75
    +35.27 (+3.39%)
     
  • FTSE 100

    7,083.37
    +102.39 (+1.47%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

Clovis Oncology to Announce Fourth Quarter and Year-End 2020 Financial Results and Host Webcast Conference Call on February 23

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter and year-end 2020 financial results on Tuesday, February 23, 2021, before the open of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 8:30 a.m. ET to discuss the Company’s results in greater detail.

The conference call will be simultaneously webcast on the Clovis Oncology website www.clovisoncology.com, and a replay of the webcast will be available for 30 days.

Dial-in numbers for the conference call are as follows: US participants (877) 698-7048, International participants (647) 689-5448, conference ID: 5869256.

About Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado; please visit www.clovisoncology.com for more information, including additional office locations in the U.S. and Europe.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210217005190/en/

Contacts

Clovis Investor Contacts:
Anna Sussman
303.625.5022
asussman@clovisoncology.com

Breanna Burkart
303.625.5023
bburkart@clovisoncology.com